Ras-MAPK Pathways

Chan, Ariane

doi:10.1126/stke.2712005tr5

Cited by 9 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As one of the most distinctive members of mitogen‐activated protein kinase family, the pathway for ERK is synonymous with cell proliferation. The expression of YKL‐40 is related to expression of phosphorus ERK1/2, which is strongly associated with poor response to radiotherapy and negative results . In addition, Zhang et al showed that the expression of phosphorus ERK1/2 significantly decreases in U87 cells when YKL‐40 extinguishes.…”

Section: Discussionmentioning

confidence: 99%

“…The expression of YKL-40 is related to expression of phosphorus ERK1/2, which is strongly associated with poor response to radiotherapy and negative results. 8,34 In addition, Zhang et al 8 showed that the expression of phosphorus ERK1/2 significantly decreases in U87 cells when YKL-40 extinguishes. Considering the important role of the PI3K signaling pathway in expression of YKL-40 and its expression by resveratrol through the PI3K signaling pathway and, on the other hand, considering that probably prednisolone can It's effects of apoptotic, anti-inflammatory, and inhibition of growth and proliferation of cancer cells through the same signaling pathway is done.…”

Section: Resveratrol and Prednisolone Downregulate Ykl-40 Protein In ...mentioning

confidence: 99%

“…Considering the important role of the PI3K signaling pathway in expression of YKL-40 and its expression by resveratrol through the PI3K signaling pathway and, on the other hand, considering that probably prednisolone can It's effects of apoptotic, anti-inflammatory, and inhibition of growth and proliferation of cancer cells through the same signaling pathway is done. 8,[34][35][36][37][38][39][40] Therefore, it is thought that these effects of resveratrol and prednisolone on the expression of YKL-40 may occur through the signaling pathway of PI3K. To prove this hypothesis, further research is needed on this topic.…”

Section: Resveratrol and Prednisolone Downregulate Ykl-40 Protein In ...mentioning

confidence: 99%

See 2 more Smart Citations

The role of tumor suppressor of resveratrol and prednisolone by downregulation of YKL‐40 expression in CCRF‐CEM cell line

Heydarabad

Baharaghdam

Azimi

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Background: Acute lymphoblastic leukemia (ALL) is characterized by excessive accumulation of lymphoblast and progenitors. Leukemia is the most common cancer in children and ALL is the most common subtype. Many studies have shown that the YKL-40 gene is one of the most widely expressed genes in tumors, including leukemia, but not in healthy blood cells. Clinical studies have shown that serum YKL-40 levels have a positive correlation with tumor expansion, in addition to being a prognostic agent independent of a short relapse-free interval, as well as a brief overall survival in patients with various cancers. The previous study shows that YKL-40 is closely related to the degree of pathology or degree of human leukemia pathology and plays an important role in cell proliferation. Hence, the YKL-40 can be an attractive target in designing anticancer therapies. Methods: CCRF-CEM cells were treated with resveratrol and prednisolone. For analysis of YKL-40 expression changes under medication, real-time polymerase chain reaction (PCR) and Western blot techniques were used at resonating intervals of 24 and 48 hours. Results: The effect of 15, 50, and 100 μM resveratrol and 700 μM of prednisolone on CCRF-CEM cells reduced YKL-40. The YKL-40 gene was quantitatively measured using RT-PCR. The Western blot method was used to evaluate changes in the expression of YKL-40 protein. Conclusion: In this study, we first evaluated YKL-40 expression and resveratrol and prednisolone effect on YKL-40 in ALL. This finding supports the idea of targeting YKL-40 as a new drug treatment of ALL and extends the use of resveratrol in antileukemia research. K E Y W O R D S acute lymphoblastic leukemia, gene expression, prednisolone, resveratrol, YKL-40 gene

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Resveratrol and Prednisolone Downregulate Ykl-40 Protein In ...mentioning

confidence: 99%

Section: Resveratrol and Prednisolone Downregulate Ykl-40 Protein In ...mentioning

confidence: 99%

See 1 more Smart Citation

The role of tumor suppressor of resveratrol and prednisolone by downregulation of YKL‐40 expression in CCRF‐CEM cell line

Heydarabad

Baharaghdam

Azimi

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

Cochrane Review: Interventions for infantile haemangiomas (strawberry birthmarks) of the skin

Leonardi‐Bee

Batta

O’Brien

et al. 2012

Evid.‐Based Child Health

View full text Add to dashboard Cite

BackgroundInfantile haemangiomas (also known as strawberry birthmarks) are soft, raised swellings of the skin which are usually uncomplicated and tend to regress spontaneously over time. Some haemangiomas occur in high‐risk areas or can develop complications; therefore, intervention may be necessary. Various interventions have been proposed, but it is unclear whether any of these interventions are effective.ObjectivesTo assess the effects of interventions for infantile haemangiomas.Search methodsWe searched the following databases up to March 2011: the Cochrane Skin Group Specialised Register, the Cochrane Central Register of Controlled Trials (Clinical Trials) in The Cochrane Library, MEDLINE, EMBASE, PsycINFO, AMED (Allied and Complementary Medicine), LILACS (Latin American and Caribbean Health Science Information database), CINAHL, and reference lists of articles. We also searched online trials registries for ongoing trials and grey literature.Selection criteriaWe included children with haemangiomas.Data collection and analysisTwo authors independently screened titles, abstracts, and the full text of publications; extracted data; and assessed risk of bias.Main resultsWe included 4 studies with a total of 271 participants.One randomised controlled trial (RCT) compared pulsed dye laser (PDL) therapy versus the 'wait and see' approach. At one year PDL was significantly more likely to result in complete clearance. The risk ratio (RR) was 6.10 (95% CI [confidence interval] 1.89 to 19.64); however, there was no difference when clearance was defined as 'complete or minimal residual signs'. Redness was significantly less pronounced in the PDL group, but no differences were seen for height or surface area. Significant increases in atrophy and skin hypopigmentation were seen in the PDL group.One very old RCT assessed radiation versus mock‐radiation; there was no significant difference in clearance at six years (RR 1.08, 95% CI 0.63 to 1.87) between the groups, irrespective of the size of the haemangioma and the skin colour.In one small RCT there was a significantly greater reduction in size of the haemangioma with oral prednisolone compared to intravenous methylprednisolone at three months (mean difference [MD] was 58 mm [95% CI 29.24 to 86.76]), and one year. Similar adverse events occurred in both groups.In another small RCT there was a significant reduction in the surface area of the haemangioma with bleomycin compared to the control (RR 21, 95% CI 1.34 to 328.86).Authors' conclusionsThis review has found limited evidence from individual RCTs to support some of the existing interventions (corticosteroid and PDL) for infantile haemangiomas. There is a need for further high‐quality RCTs to validate the findings from these studies, and RCTs to assess the effect of other treatments, in particular relating to propranolol.Plain Language SummaryTreatments for strawberry birthmarks of the skin in infants and childrenInfantile haemangiomas are soft, raised swellings on the skin, often with a bright, red surface. They are a non‐cancerous overgrowth of blood vessels in the skin. They are commonly known as 'strawberry birthmarks', 'strawberry naevi', or 'capillary haemangiomas'. They occur in five per cent of babies, with the majority appearing within the first few weeks of life, and reach their full size at about three to six months of age. The vast majority are uncomplicated and will shrink on their own by five to seven years of age and require no further treatment. However, some infantile haemangiomas may occur in high‐risk areas (such as near the eyes and nose which can result in impairment to vision and airway obstruction, respectively) and some of them are disfiguring and psychologically distressing to the children and their parents. Some may also develop complications so early medical treatment may be necessary. Corticosteroids are currently the standard treatment; however, it is not known which of a variety of treatments is best.Four trials (ranging from 20 to 121 participants) were included in this review. Two assessed treatments which are no longer used (bleomycin and radiation), with neither trial finding clinically important improvements. From the other two trials limited evidence in relation to clinically important improvements were seen.One trial assessed the use of photodynamic laser (PDL) therapy. Haemangiomas were more likely to completely clear with PDL when compared to a 'wait and see' approach at one year. However, there were significant side‐effects, and it was noted that most of the birthmarks treated with PDL would have resolved naturally over time.One trial compared an oral corticosteroid (prednisolone) with an intravenous corticosteroid. Haemangiomas were more likely to reduce in size using the oral corticosteroid as compared to the intravenous corticosteroid at three months and one year. Similar numbers of side‐effects were being seen in both groups.We found eight ongoing trials, four of which were designed to assess the effectiveness of oral propranolol either against placebo or an oral corticosteroid. Propranolol has become the second‐line treatment since the publication of the protocol of this review in 2007; therefore, it is important that this review is updated within the next three years so these studies can be assessed and added to the evidence base to inform clinical practice.There is limited evidence of the effectiveness of treatments for those birthmarks that require treatment because the data has come from small trials. The treatments used for haemangiomas need to be tested in large, well‐designed trials.

show abstract